Kalafo ea Pele le Feela e Fetang Nako e Telele ea Ente ea HIV

Janssen Pharmaceutical Companies of Johnson & Johnson kajeno e phatlalalitse hore US Food and Drug Administration (FDA) e amohetse ntjhafatso ea label bakeng sa CABENUVA (cabotegravir le rilpivirine), e fang litsebi tsa bophelo bo botle le batho ba phelang le kokoana-hloko ea human immunodeficiency virus (HIV-1) United States. khetho ea ho qala kalafo ena ea ente hang ka khoeli kapa likhoeli tse peli ntle le tlhoko ea mokhahlelo oa pele oa molomo (lipilisi tsa cabotegravir le rilpivirine tsa letsatsi le letsatsi, tse nooang khoeli e le 'ngoe pele ho qala liente tsa cabotegravir le rilpivirine). Lintlha tsa kliniki li bonts'itse hore mokhoa ona o bonts'a boemo bo ts'oanang ba polokeho le ts'ebetso ka nako le ntle le nako ea ho etella pele ka molomo. CABENUVA e ile ea ntlafatsoa hammoho e le karolo ea tšebelisano 'moho le ViiV Healthcare mme e theha boitlamo ba Janssen ba lilemo tse mashome ho loants'a HIV.

"Re na le rekoto e netefalitsoeng ea ho tlisa liphekolo tse ncha ho batho ba phelang le tšoaetso ea HIV, 'me boitlamo ba rona ba ho kenya letsoho tsoelopeleng e ncha ea saense ha bo so thekesele," ho boletse James Merson, Ph.D., Global Therapeutic Area Head, Infectious Diseases, Janssen Research. & Development, LLC. "Ka ketsahalo ena e atolositsoeng ea li-label, Janssen o fana ka tsela e 'ngoe e nolofatsang boemo ba kalafo bakeng sa batho ba phelang le HIV ba US ba fuoeng kalafo ea CABENUVA."

CABENUVA ke mokhoa oa pele le o felletseng oa kalafo oa HIV oa nako e telele 'me o amohetsoe US e le kalafo hang ka khoeli kapa likhoeli tse peli bakeng sa HIV-1 ho batho ba baholo ba hatelletsoeng ke vaerase (HIV-1 RNA <50 copies/mL) ka mokhoa o tsitsitseng oa li-antiretroviral o se nang nalane ea ho hloleha ha kalafo le ho sa tsejoe kapa ho belaelloang hore o hanana le cabotegravir kapa rilpivirine. E na le ViiV Healthcare's cabotegravir e fanyehiloeng ka nako e telele ka pitseng ea lethal dose e le 'ngoe le rilpivirine e fanyehiloeng nako e telele ka pitseng ea lethal dose le le leng, sehlahisoa sa Janssen Sciences Ireland Unlimited Company, e 'ngoe ea Janssen Pharmaceutical Companies of Johnson & Johnson.

"Ho Janssen, re motlotlo ho tsoela pele ka likhetho tse tšehetsang bakuli le ho thusa bafani ba tlhokomelo ea bophelo ho fumana merero ea phekolo ea motho ka mong e sebetsanang le litlhoko le maemo a ikhethang bakeng sa batho ba phelang le HIV," ho boletse Candice Long, Mopresidente, Mafu a Tšoaetso & Vaccines, Janssen Therapeutics. , Karolo ea Lihlahisoa tsa Janssen, LP. "Ho fana ka mefuta e fapaneng ea liphekolo tsa HIV ho bohlokoa ho thusa ho fihlela litlhoko tsena tse fapaneng tsa kalafo, 'me re lumela hore CABENUVA ke khetho e molemo bakeng sa bakuli le bafani bao re ba sebeletsang."

Tumello ena ea US FDA e ipapisitse le Sephetho sa Beke ea 124 ea FLAIR (Sephetho sa Pele sa Nako e Telele ea Injectable) se bonts'itseng hore ho bile le liphetho tse ts'oanang mabapi le tlhokomelo ea khatello ea mali, polokeho, mamello le pharmacokinetics ho batho ba qalang liente tsa cabotegravir le rilpivirine ka molomo kapa ntle le eona. etella pele.